Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MCARH109 and MCARH125 in Relapsed or Refractory Multiple Myeloma
NCT05431608Phase 1Active, not recruiting
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Jun 2022
- Primary completion
- Jun 2027
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label trial of MCARH125 and GPRC5D-CAR-T in multiple myeloma (MM) (5 arms), sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoint: Maximum Tolerated Dose at 24 months. Started Jun 2022; status: active, not recruiting.
02
Drugs
MCARH125GPRC5D-CAR-T
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT05431608.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05431608.